VARILRIX® PRODUCT INFORMATION

Varicella Vaccine, live attenuated

DESCRIPTION
VARILRIX is a lyophilised preparation of the live attenuated Oka strain of varicella-zoster virus, obtained by propagation of the virus in MRC5 human diploid cell culture.

Each 0.5ml dose of the reconstituted vaccine contains not less than $10^{3.3}$ plaque-forming units (PFU) of the varicella-zoster virus. The vaccine also contains amino acids, human albumin, lactose, neomycin sulphate, and polyalcohols. VARILRIX does not contain a preservative.

The manufacture of this product includes exposure to bovine derived materials. No evidence exists that any case of vCJD (considered to be the human form of bovine spongiform encephalopathy) has resulted from the administration of any vaccine product.

VARILRIX meets the World Health Organisation requirements for biological substances and for varicella vaccines.

CLINICAL PHARMACOLOGY
VARILRIX produces an attenuated clinically inapparent varicella infection in susceptible subjects, with the subsequent production of varicella-specific antibodies.

CLINICAL TRIALS
Efficacy studies
Two randomised placebo-controlled trials have been performed.
- Children (n=327) 12 - 30 months of age were administered one dose of vaccine and followed up for an average of 29.3 months. Efficacy against clinical varicella of any severity was calculated as 88% (95% CI 72-96). The median number of vesicles in breakthrough cases in children was 1 (placebo group median = 30).
- Adults (n=233) were administered two doses of vaccine at an interval of 2 months and then followed up for an average of 18 months. Efficacy against clinical varicella of any severity was conservatively estimated at 75.9% (95% CI 43.8-89.7); errors in the methodology used in this trial imply that efficacy cannot be accurately determined. Of the 11 vaccinees with breakthrough disease, only 2 had >200 vesicles, compared with 57% of the unvaccinated subjects.

In both trials, subjects who responded to vaccination and who later developed breakthrough varicella had fewer lesions than unvaccinated individuals, demonstrating attenuation of varicella infection for those subjects who were not protected completely.
**Immunogenicity Studies**

In subjects aged 9 months to 36 months (n=1573), the overall seroconversion rate following administration of VARILRIX was greater than 98.0% when measured 6 weeks post vaccination. Seroconversion was defined as postvaccination titres ≥4 in a subject with prevaccination titres <4, and was determined using a commercial indirect immunofluorescence assay.

The following table presents the range of results seen in 13 clinical trials evaluating the immunogenicity of VARILRIX in infants, adolescents and adults. GMTS are variable across studies, a recognised characteristic of live viral vaccines.

<table>
<thead>
<tr>
<th>AGE RANGE</th>
<th>N</th>
<th>Seroconversion rate</th>
<th>GMT</th>
</tr>
</thead>
<tbody>
<tr>
<td>9-36 mths</td>
<td>1467</td>
<td>92.9 - 100</td>
<td>31 - 104</td>
</tr>
<tr>
<td>≥ 12 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Dose 1</td>
<td>350</td>
<td>82.3 - 94.1</td>
<td>20 - 40</td>
</tr>
<tr>
<td>- Dose 2</td>
<td>271</td>
<td>100</td>
<td>167 - 236</td>
</tr>
</tbody>
</table>

An increase in the antibody levels of vaccinees who remained seropositive was seen in studies which assessed persistence of antibody response. This suggests boosting due to exposure to varicella virus in the community. The duration of persistence of antibody in the absence of such boosting is unknown.

**INDICATIONS**

VARILRIX is indicated for active immunisation against varicella of healthy subjects from 9 months of age.

Groups who would particularly benefit from vaccination include:

- Non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children’s day-care centres
- Non-immune parents of young children
- Non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease

**CONTRAINDICATIONS**

VARILRIX should not be administered to subjects with known hypersensitivity to any component of the vaccine.
VARILRIX is contraindicated in subjects with known systemic hypersensitivity to neomycin, but a history of contact dermatitis to neomycin is not a contraindication.

VARILRIX is contraindicated during pregnancy. Pregnancy should be avoided for three months after vaccination (see WARNINGS AND PRECAUTIONS).

Individuals receiving immunosuppressive therapy are more susceptible to infections than healthy individuals. Vaccination with live attenuated varicella vaccine can result in a more extensive vaccine associated rash or disseminated disease in individuals on immunosuppressant doses of corticosteroids.

Individuals with primary and acquired immunodeficiency states, including those who are immunosuppressed in association with AIDS or other clinical manifestations of infections with human immunodeficiency virus; cellular immune deficiencies; hypogammaglobulinemic and dysgammaglobulinemic states; leukaemias, lymphomas and blood dyscrasias.

A family history of congenital or hereditary immunodeficiency, unless the immune competence of the potential vaccine recipient is demonstrated.

As with other vaccines, the administration of VARILRIX should be postponed in subjects suffering from acute severe febrile illness. In healthy subjects, the presence of a minor infection, however, is not a contraindication to immunisation.

**PRECAUTIONS**

**VARILRIX should under no circumstances be administered intravenously.** VARILRIX should not be administered intradermally.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of rare anaphylactic reactions following the administration of a vaccine.

Transmission of the Oka virus to seronegative contacts of a vaccinee has been shown to occur at an extremely low rate. Transmission has not been reported if the vaccinee does not have vaccine-associated cutaneous lesions. The mild nature of the rash which developed in the healthy contacts indicates that the virus remains attenuated after passage through human hosts. Vaccine recipients should attempt to avoid contact with susceptible high risk individuals for up to 6 weeks, where possible.
As for any vaccine, vaccination with Varilrix may not result in protection from subsequent infection with varicella virus in 100% of subjects (see CLINICAL TRIALS).

The safety and efficacy of Varilrix has not been established in persons who are known to be infected with HIV, with or without evidence of immunosuppression.

The duration of protection from varicella infection with Varilrix is unknown. The need for and timing of booster doses is uncertain at present. In a highly vaccinated population, immunity of some individuals may wane due to lack of exposure to natural varicella as a result of shifting epidemiology.

It is not known whether Varilrix given immediately after exposure to wild varicella virus will prevent illness. Results of a small household contact study using another live varicella virus vaccine containing the same varicella strain as Varilrix suggested that some protection was provided by that vaccine when vaccination occurred within 72 hours of exposure.

There are inadequate data to assess the incidence and severity of herpes zoster (shingles) after vaccination with Varilrix.

**Use in Pregnancy**
VARILRIX use is contraindicated in pregnant women as the possible effects on foetal development are unknown (see CONTRAINDICATIONS). Pregnancy should be avoided for three months after vaccination.

**Use in Lactation**
The effect on breast fed infants of the administration of VARILRIX to their mothers has not been evaluated in clinical studies.

**Interactions**
VARILRIX should not be mixed in the same syringe with other vaccines. Different injection sites should always be used.
There was no reduction in safety and immunogenicity when Varilrix was given concomitantly, at a separate site, using a separate syringe, with a Measles-Mumps-Rubella vaccine and with a Diphtheria-Tetanus-Acellular pertussis vaccine. There are no data on concomitant administration with other live or inactivated vaccines or on administration of vaccines after Varilrix has been given. If it is necessary to administer more than 1 live virus vaccine at the same time, these may be given at the same visit at different sites. If not given on the same day, the live viral vaccinations should be separated by an interval of at least 4 weeks.
Reactivity to tuberculin skin testing may be suppressed in patients receiving live virus vaccination. If tuberculin testing is indicated, it should be done preceding or at the same time as such immunisation. If the test is not administered at the same time, an interval of 4-6 weeks should be allowed between tuberculin skin testing and immunisation with live virus vaccines.

VARILRIX may be administered at the same time as a measles-containing vaccine. If this is not possible, an interval of at least one month should elapse before the measles-containing vaccine is given. Measles vaccination may lead to short lived suppression of the cell mediated immune response.

In subjects who have received immune globulin or a blood transfusion, immunisation should be delayed for at least three months because of the likelihood of vaccine failure due to passively acquired varicella antibodies.

Salicylates should be avoided for 6 weeks after varicella vaccination as Reye's syndrome has been reported following the use of salicylates during natural varicella infection.

**ADVERSE REACTIONS**

**Clinical Trial Data**

More than 5500 subjects aged 9 months and over have been vaccinated with VARILRIX in ongoing and completed trials. Pain at the injection site was usually described as mild, and swelling and redness >2cm in diameter were infrequently observed.

No serious adverse events were considered to be unequivocally related to vaccination.

In the four week follow-up of a double-blind, placebo-controlled efficacy study in children aged 12-30 months (n=513), there was no significant difference in the nature or incidence of symptoms in subjects who received the vaccine compared to placebo.

In the adolescent/adult studies there was no increase in reactogenicity following the second dose. The incidence of symptoms after vaccination of seropositive individuals was not different from that of seronegative subjects.
Percentage of Vaccinees reporting solicited symptoms with respect to placebo recipients

<table>
<thead>
<tr>
<th></th>
<th>Children</th>
<th>Adolescents</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Varilrix</td>
<td>placebo</td>
<td>Varilrix</td>
</tr>
<tr>
<td></td>
<td>(N = 340)</td>
<td>(N = 172)</td>
<td>(N = 333)</td>
</tr>
<tr>
<td>Local reactions</td>
<td>8.2%</td>
<td>7.6%</td>
<td>2.4%</td>
</tr>
<tr>
<td>Fever* (temperature ( \geq 38^\circ C )) (( &gt; 39.5^\circ C ))</td>
<td>51.8% ( (5.9% )</td>
<td>51.2% ( (5.2% )</td>
<td>1.8% ( (0% )</td>
</tr>
<tr>
<td>Rash (any) (varicella-like vesicular rash)</td>
<td>37.4% ( (6.2% )</td>
<td>36.6% ( (5.2% )</td>
<td>0.6% ( (0% )</td>
</tr>
</tbody>
</table>

Total post-vaccination period for evaluation of adverse events: 42 days for children (28 days for local reactions and fever), 98 days for adolescents and 126 days for adults.

*Not solicited in all trials.

AE reporting rate was highly variable, depending on study methodology.

In non-placebo controlled trials, the incidence of local and general adverse events varied widely, which may in part reflect the differing methodologies used for collection of the safety data.

The adverse events listed below are by body system and are categorised by frequency according to the following definitions: very common events reported at a frequency of greater or equal to 1/10 patients; common events are reported at a frequency of less than 1/10 but greater or equal to 1/100 patients; uncommon events reported at a frequency of less than 1/100 but greater or equal to 1/1000; rare events reported at a frequency of less than 1/1000 but greater or equal to 1/10000; very rare events reported at a frequency of less than 1/10000 patients. Causality has not necessarily been established.

**Events reported in children**

**Local reactions:** Very common: Pain at the injection site; redness, swelling; Common: swelling (>2cm), redness (>2cm), injection site reaction; Uncommon: contact dermatitis

**Body as a whole:** Common: Fever, rash, injury, viral infection; Uncommon: Varicella-like rash, fever >39°C, fatigue, pain, infection, bacterial infection, fungal infection; Uncommon: malaise

**Skin and appendages:** Common: Pruritis, Uncommon: Eczema, purpura, sweat gland disorder, dry skin; Rare: urticaria

**Gastrointestinal:** Common: Diarrhoea, abdominal pain, vomiting, toothache; Uncommon: Nausea, dyspepsia

**Musculo-skeletal:** Uncommon: Arthralgia, myalgia
**Central Nervous System:**  *Common:* Headache, nervousness;  *Uncommon:* somnolence, irritability

**Respiratory:**  *Common:* URTI, coughing, pharyngitis, rhinitis;  *Uncommon:* asthma, sinusitis, respiratory disorder

**Special Senses:**  *Common:* conjunctivitis, otitis media;  *Uncommon:* earache

**Events reported in adults (after dose 1 and/or dose 2)**

**Local reactions:**  *Very common:* Pain at the injection site, injection site reaction, redness, injection site inflammation;  *Common:* injection site mass

**Body as a whole:**  *Very Common:* Fever;  *Common:* fatigue, chest pain, injury, malaise; infection viral;  *Uncommon:* Varicella-like rash

**Skin and appendages:**  *Common:* Dermatitis, pruritis, rash;  *Rare:* urticaria

**Gastrointestinal:**  *Common:* Diarrhoea, abdominal pain, vomiting, nausea, gastroenteritis

**Central Nervous System:**  *Very common:* headache;  *Common:* dizziness, migraine, somnolence;  *Uncommon:* irritability

**Respiratory:**  *Very common:* URTI, pharyngitis;  *Common:* asthma, bronchitis, coughing, sinusitis, rhinitis, sputum increased

**Haematologic/lymphatic:**  *Common:* Lymphadenopathy, lymphadenopathy cervical

**Musculo-skeletal:**  *Common:* Arthralgia, back pain, myalgia

**Special Senses:**  *Rare:* conjunctivitis

**Post-marketing Data**

More than 15 million doses of Varilrix have been distributed since first approval in October 1994.

The following adverse reactions have been reported  *very rarely:*  
Infections and infestations: encephalitis viral, herpes zoster* and varicella  
Immune system disorders: hypersensitivity, anaphylactic reactions  
Nervous system disorders: convulsions, cerebellar ataxia*
* This reaction reported after vaccination is also a consequence of wild-type varicella infection. There is no indication of an increased risk of its occurrence following vaccination compared with wild-type disease.

Varicella-like rashes occurring >2 weeks after vaccination have been reported very rarely. The median number of vesicles reported was 50, and fever was reported as present in approximately one-third of all cases of breakthrough disease.

**DOSAGE AND ADMINISTRATION**

VARILRIX should be administered as a single dose by subcutaneous injection only. The upper arm (deltoid region) is the preferred site of injection.

UNDER NO CIRCUMSTANCES SHOULD VARILRIX BE ADMINISTERED INTRAVENOUSLY. VARILRIX should not be administered intradermally.

**Dosage**

**Infants and Children (aged 9 months up to and including 12 years of age)**

A single 0.5ml reconstituted dose of VARILRIX is used for immunisation of infants and children.

**Adolescents and Adults (13 years of age and over)**

Two 0.5ml doses of reconstituted VARILRIX, administered at least 6 weeks apart, are required.

**Administration**

VARILRIX should be reconstituted by adding 0.5 mL of sterile water diluent to the vaccine vial containing the pellet. After the addition of the diluent to the pellet, the mixture should be well shaken until the pellet is completely dissolved in the diluent.

Due to minor variations of its pH, the colour of the reconstituted vaccine may vary from a clear peach to a pink coloured solution. Vaccines should be inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either being observed, discard the vaccine.

After reconstitution, it is recommended that the vaccine be injected as soon as possible. However, it has been demonstrated that the vaccine may be kept for up to 90 minutes at room temperature (25°C) or up to 8 hours in the refrigerator (2°C to 8°C). If not used within these timeframes, the reconstituted vaccine must be discarded. For use in a single individual, on one occasion only. Varilrix contains no antimicrobial agent. Use once only and discard any residue.
Alcohol and other disinfecting agents must be allowed to evaporate from the skin before the injection of the vaccine as they may inactivate the virus.

OVERDOSAGE
Cases of accidental administration of more than the recommended dose of Varilrix have been reported. Amongst these cases, the following adverse events were reported: lethargy and convulsions. In the other cases reported as overdose there were no associated adverse events.

STORAGE
The lyophilised vaccine should be stored in a refrigerator between +2°C and +8°C. The diluent can be stored in the refrigerator or at ambient temperatures. The lyophilised vaccine is not affected by freezing.

The shelf life of VARILRIX is 24 months from the date of manufacture if stored between +2°C and +8°C.

When supplies of VARILRIX are distributed from a central cold store, it is necessary to arrange transport under refrigerated conditions.

PRESENTATIONS
VARILRIX is presented as a slightly cream to yellowish or pinkish coloured pellet in a glass vial. The sterile diluent is clear and colourless and presented in ampoules and prefilled syringes.

VARILRIX is supplied as:
- a single dose vial of lyophyllised vaccine with diluent syringe or ampoule included,
- a box containing 10 single dose vials of lyophyllised vaccine with 10 diluent syringes included,
- a box containing 10 single dose vials of lyophyllised vaccine, and
- sterile diluent in boxes of 10 ampoules is supplied separately.

The ampoules, vials and prefilled syringes are made of neutral glass type I, which conforms to European Pharmacopoeia Requirements.
Not all presentations and pack sizes may be marketed.

MANUFACTURER
GlaxoSmithKline Biologicals SA
Rue de l’Institut
1330 Rixensart Belgium